Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.61 USD | -1.37% | -0.28% | +18.03% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 40.03M | Capitalization | 308M |
---|---|---|---|---|---|
Net income 2024 * | -268M | Net income 2025 * | -255M | EV / Sales 2024 * | - |
Net cash position 2024 * | 518M | Net cash position 2025 * | 404M | EV / Sales 2025 * | -2.38 x |
P/E ratio 2024 * |
-1.15
x | P/E ratio 2025 * |
-1.21
x | Employees | 74 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.44% |
Latest transcript on Atea Pharmaceuticals, Inc.
1 day | -0.81% | ||
1 week | +1.67% | ||
Current month | -1.08% | ||
1 month | -1.35% | ||
3 months | -19.74% | ||
6 months | +27.08% | ||
Current year | +20.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 68 | 12-11-30 | |
Andrea Corcoran
DFI | Director of Finance/CFO | 61 | 13-11-30 |
Maria Horga
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 19-08-31 |
Barbara Duncan
BRD | Director/Board Member | 59 | 20-09-30 |
Chief Executive Officer | 68 | 12-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 3.6 | -1.64% | 124 125 |
24-05-24 | 3.66 | -0.81% | 148,489 |
24-05-23 | 3.69 | -3.40% | 164,232 |
24-05-22 | 3.82 | +5.82% | 493,535 |
24-05-21 | 3.61 | +0.28% | 167,612 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.00% | 308M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.48% | 22.1B | |
-9.35% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AVIR Stock